IRX2

Across TCGA pan-cancer cohorts, IRX2 Mutation is linked to patient survival in 10 of 34 cancer types, making it a survival-associated IRX2 data layer compared with 23 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in thyroid carcinoma (THCA), where higher IRX2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IRX2 expression acts as an unfavorable survival marker.

THCA, LIHC, and READ are the cancer types where IRX2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THCA	OS	Median	All	0.098	0.941	<.001	42	view →
LIHC	OS	Median	All	0.028	0.777	<.001	24	view →
READ	DFS	Median	All	0.084	0.845	<.001	12	view →
COAD	DFS	Median	All	0.219	0.696	.001	12	view →
SKCM	OS	Median	III,IV	0.556	0.802	<.001	11	view →
KIRC	DFS	Median	All	0.198	0.796	.005	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
KIRP	OS	Median	All	0.192	0.705	.015	4	view →
BLCA	OS	Median	III,IV	0.187	0.684	.006	3	view →
LUAD	OS	Median	All	0.644	0.836	.039	2	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

IRX2–THCA (OS)

Open the THCA breakdown →